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Abstract
Purpose To characterize exposure–response relationships
of AMG 386 in a phase 2 study in advanced ovarian cancer
for the facilitation of dose selection in future studies.
Methods A population pharmacokinetic model of
AMG 386 (N = 141) was developed and applied in an
exposure–response analysis using data from patients
(N = 160) with recurrent ovarian cancer who received
paclitaxel plus AMG 386 (3 or 10 mg/kg once weekly) or
placebo. Reduction in the risk of progression or death with
increasing exposure (steady-state area under the con-
centration-versus-time curve [AUCss]) was assessed using
Cox regression analyses. Confounding factors were tested
in multivariate analysis. Alternative AMG 386 doses were
explored with Monte Carlo simulations using population
pharmacokinetic and parametric survival models.
Results There was a trend toward increased PFS with
increased AUCss (hazard ratio [HR] for each one-unit
increment in AUCss, 0.97; P = 0.097), suggesting that the
maximum effect on prolonging PFS was not achieved
at the highest dose tested (10 mg/kg). Among patients
with AUCss C 9.6 mg h/mL, PFS was 8.1 months versus
5.7 months for AUCss\9.6 mg h/mL and 4.6 months for
placebo. No relationship between AUCss and grade C3
adverse events was observed. Simulations predicted that
AMG 386 15 mg/kg once weekly would result in an
AUCss C 9.6 mg h/mL in [90% of patients with median
PFS of 8.2 months versus 5.0 months for placebo (HR
[15 mg/kg vs. placebo], 0.56).
Conclusions Increased exposure to AMG 386 was asso-
ciated with improved clinical outcomes in recurrent ovar-
ian cancer, supporting the evaluation of a higher dose in
future studies.
Keywords AMG 386   Ovarian cancer   Paclitaxel  
Pharmacokinetics   Population pharmacokinetic/
pharmacodynamic modeling   Exposure–response analysis
Introduction
Quantitative drug and disease modeling techniques are
increasingly applied to today’s drug development process
to inform critical decisions. By integrating complex data,
the resulting deeper understanding of a drug’s action can
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design selection, facilitate the development of combination
therapies, and provide a better understanding of risk–beneﬁt
ratios [1, 2]. Use of such pharmacometric techniques may
be particularly valuable in oncology, where phase 2 studies
have historically been poor positive predictors of phase 3
outcomes [3, 4]. A key goal during early-phase develop-
ment of novel cancer therapeutics is ﬁnding a dose that
maximizes clinical beneﬁt while maintaining an acceptable
safety proﬁle [5–7]. Because dose-ranging phase 2 studies
are not frequently conducted in oncology [8], selecting an
appropriate dose for a registrational study can present a
considerable challenge. However, poor dose selection is one
likely contributor to the historically limited ability of
phase 2 studies to predict success of subsequent phase 3
trials [3, 4]. Population pharmacokinetic/pharmacodynamic
modeling isan innovative tool that has shown promise when
applied to the prediction of clinical endpoints [9, 10],
identiﬁcation of factors inﬂuencing clinical endpoints [11],
and dose selection [12, 13]. Importantly, the US Food and
Drug Administration (FDA) has suggested that exposure–
response models may provide useful information for end-
of-phase-2 dose-selection decisions [14]. Speciﬁcally, the
FDA’s Critical Path Initiative [15] has identiﬁed quantita-
tive modeling as a technique that may reduce uncertainty
regarding dose selection.
AMG 386 (previously referred to as 2xCon4) is an
investigational peptide-Fc fusion protein that mediates
antiangiogenic effects by potently and selectively inhibit-
ing the interaction of angiopoietin-1 and angiopoietin-2
with Tie2 [16]. Primary endpoint results from a phase 2
study of AMG 386 in combination with weekly paclitaxel
for the treatment of recurrent ovarian cancer showed longer
median progression-free survival (PFS) for patients
receiving AMG 386 at 10 and 3 mg/kg once weekly (QW),
compared with placebo (the data are described in the pri-
mary analysis [17]). Additional dose-exposure analyses
suggested a dose–response effect across treatment arms.
Although the study strongly suggests that AMG 386 has
antitumor activity in recurrent ovarian cancer, the dose–
response effect raises the question of whether the tested
doses maximized the risk–beneﬁt ratio. The objective of
the present analysis was to use population pharmacoki-
netic/pharmacodynamic models to explore whether doses
of AMG 386 higher than those assessed in the phase 2
clinical study might result in further improvements in PFS
while maintaining acceptable toxicity. Speciﬁcally, the
models comprised a characterization of the pharmacoki-
netics of AMG 386 in recurrent ovarian cancer patients, an
exposure–response analysis to assess the relationship
between AMG 386 exposure and efﬁcacy/toxicity end-
points, and exploration of potential clinical outcomes at
doses higher than those evaluated in the phase 2 study.
Methods
Data sources
AMG 386 serum concentration-versus-time data for the
population pharmacokinetic analysis were obtained from
two clinical studies: a phase 1 ﬁrst-in-human monotherapy
study [18] in advanced solid tumors (n = 32) and a phase 2
study [17] in advanced ovarian cancer (n = 109). The
phase 1 study was a sequential dose-escalation study of
AMG 386 administered intravenously QW at 5 doses (0.3,
1, 3, 10, and 30 mg/kg) with 4–16 patients per dose group
[18]. Intensive serum samples were collected at the end of
infusion and at 2, 6, 24, 48, and 96 h after the infusion at
weeks 1 and 4. Sparse pharmacokinetic (peak or trough)
samples were collected before each weekly AMG 386
administration. The phase 2 study evaluated weekly pac-
litaxel plus AMG 386 at 10 mg/kg QW and 3 mg/kg QW,
or placebo [17]. Pharmacokinetic samples were collected
predose at weeks 1, 3, 5, and 9; every 8 weeks thereafter;
and at the end of infusion at weeks 1 and 5. All patients
provided written informed consent, and the study protocols
were approved by an ethics committee at each participating
center.
Efﬁcacy and toxicity data for the exposure–response
analysis were obtained from the phase 2 study [17]. The
primary endpoint was PFS, deﬁned as the time from ran-
domization to the date of disease progression per Response
Evaluation Criteria in Solid Tumors version 1.0 [19],
clinical progression (per investigator), CA-125 progression
(Gynecologic Cancer Intergroup criteria [20]), or death.
Further study details are reported in the primary analysis
[17].
Population pharmacokinetic analysis
A linear 2-compartment model was used to describe
AMG 386 concentration data with population pharmaco-
kinetic modeling using the nonlinear mixed-effect modeling
software program NONMEM (version V, level 1.1; ICON
Development Solutions, Ellicott City, MD) [21]. An expo-
nential interindividual variability error term that assumed a
log-normal distribution was included with all pharmacoki-
neticparameters(clearance[CL],distributionclearance[Q],
and volumes of distribution for the central compartments
[Vc] and peripheral compartments) in the model. Combined
additive and proportional components were used to model
residual intraindividual random error.
Five baseline variables (weight, sex, age, serum creati-
nine, and creatinine clearance [CrCL]) were tested with
forward selection (P\0.01) and backward elimination
(P\0.005) approaches for their effects on CL and Vc [22].
CrCL was calculated based on the Cockcroft-Gault formula
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interest (total bilirubin, alkaline phosphatase, albumin,
S-aspartate aminotransferase, and S-alanine aminotrans-
ferase) were explored graphically using the base population
pharmacokinetic model (without covariates) to examine
potential associations with pharmacokinetic parameters
(CL and Vc; Supplemental Table 1). Further, the effect of
coadministration of AMG 386 with paclitaxel compared
with AMG 386 monotherapy was assessed after the
selection of physiologic covariates.
Continuous covariates such as body weight were inclu-
ded in the structural model using the following equation:
hi ¼ hTypical  
Covi
Covreferencevalue
 heff
where hi is the value of a pharmacokinetic parameter for
the ith individual; hTypical is the typical value of the phar-
macokinetic parameter for an individual having the refer-
ence value of the covariate in the population (e.g., 70 kg
for body weight); Covi is the value of the covariate for
the ith individual; Covreference value is the median of the
covariate among patients, and heff is the value of the
covariate effect on the pharmacokinetic parameter.
The evaluation of a categorical covariate effect (e.g.,
sex) on typical values of pharmacokinetic parameters was
described as follows:
If Covi ¼ value 1; then heff ¼ 1
Else; if Covi ¼ value 2; then heff ¼ heff2
hi ¼ hTypical   heff
The exposure measure in the exposure–response analysis
was the steady-state area under the concentration-versus-
time curve (AUCss), which was assessed based on
individual CL values obtained with an empirical Bayesian
post hoc estimate from the ﬁnal population pharmacokinetic
model (Supplemental Table 1) [21].
Exposure–response analysis
Kaplan–Meier curves for PFS were calculated for patients
with AMG 386 AUCss C 75th percentile (high exposure)
and AUCss\75th percentile (low exposure) and for pla-
cebo-treated patients. Univariate Cox regression models of
AUCss by PFS were used to characterize the exposure-PFS
curve. These models assumed a linear relationship between
exposure and the logarithm of the relative risk. AUCss for
patients who received placebo plus weekly paclitaxel was
set to zero. Because the relationship between exposure and
PFS may not have been linear over the entire range of study
exposures, the following subsets were analyzed: placebo
and AMG 386 3 mg/kg QW combined; AMG 386 3 mg/kg
and10 mg/kgQW combined;andAMG38610 mg/kgQW.
Multivariate Cox regression models were used to eval-
uate the effect of potential confounding factors on the
exposure-PFS curve for the AMG 386 10 mg/kg dose. They
included those affecting AMG 386 exposure (CrCL, age,
and body weight), prognostic factors (Gynecological
Oncology Group performance status, tumor type, histology,
platinum sensitivity, progression on or within 6 months of
previous chemotherapy regimen, and liver metastases), and
baseline laboratory values (serum CA-125, albumin, alka-
line phosphatase, S-aspartate aminotransferase, S-alanine
aminotransferase, creatinine, lactate dehydrogenase, and
potassium). A forward selection algorithm was used to
identify a multivariate model with up to three variables
using only data from the placebo group, a model that was
associated with PFS in the absence of AMG 386 exposure;
AUCss was added to this model and estimated for patients
in the 10 mg/kg QW treatment arm to evaluate the effect of
AMG 386 exposure on PFS when adjusting for factors with
an AMG 386-absent association with PFS.
A descriptive analysis was conducted to evaluate trends
in the incidence of severe (grade C3) AEs among patients
with AMG 386 AUCss C 75th percentile and \75th
percentile.
Simulation and dose assessment
To predict PFS at different doses, a parametric survival
model that related estimated AUCss to PFS was developed
using data from all three treatment arms in the phase 2
study. The survival function that best described the
observed PFS distribution was selected from normal, log-
normal, Weibull, logistic, log-logistic, and exponential
functions using the Akaikie Information Criterion and
diagnostic plots [9, 10, 24]. Estimation of model parame-
ters was performed using the CensorReg function in
S-PLUS (version 7.0; Insightful Corporation, Seattle, WA).
Evaluation of the selected model was conducted by
simulating PFS values from 1,000 trials (replicates) and
comparing the actual and simulated PFS curves (median
and 95% CI) across all three treatment arms. To evaluate
the AUCss distribution at different doses, random selections
of 1,000 hypothetical patients were resampled (boot-
strapped with replacements) from a total of 160 patients in
the phase 2 study. Individual plasma concentration-versus-
time proﬁles were simulated using the ﬁnal population
pharmacokinetic model including ﬁxed- and random-effect
parameters.
The population pharmacokinetic and survival models
were used to simulate AUCss at AMG 386 doses of 0, 3, 10,
and 15 mg/kg QW and to predict PFS across 1,000 repli-
cates of a simulated 1,000-patient study, respectively. The
objective of this analysis was to predict PFS following the
Cancer Chemother Pharmacol (2012) 69:1135–1144 1137
123treatment with various doses of AMG 386. Uncertainty in
the AUCss-PFS model estimation was accounted for by
sampling parameter estimates as part of the simulation
process using a previously described method [9, 10]. In
addition to the graphic comparison of the actual and pre-
dicted PFS curves, statistical estimates, including median
PFS for each treatment arm and hazard ratio (HR) relative
to placebo, were estimated and compared with the actual
values.
Results
Patients
The ﬁnal database for pharmacokinetic analysis consisted
of 1,275 evaluable serum AMG 386 concentration assess-
ments, of which 690 were from the ﬁrst-in-human phase 1
study (from 32 patients with solid tumors), and 585 were
from the phase 2 study (from 109 patients with recurrent
ovarian cancer; Supplemental Table 2). Selected baseline
characteristics of the two patient populations are summa-
rized in Supplemental Table 3. Results from the primary
analysis of the phase 2 study have been reported previously
[17].
Progression-free survival (the primary endpoint) in the
phase 2 study was 7.2 months (95% CI, 5.3–8.1) in the
AMG 386 10 mg/kg QW dose group (HR, 0.76; 95% CI,
0.49–1.18; P = 0.225) and 5.7 months (95% CI, 4.6–8.0)
in the 3 mg/kg group (HR, 0.75; 95% CI, 0.48–1.17;
P = 0.207), compared with 4.6 months (95% CI, 1.9–6.7)
for placebo [17]. Results from Tarone’s test and dose-
exposure analyses suggested a dose–response effect for
PFS across the three arms (P = 0.037).
Population pharmacokinetic analysis
AMG 386 exhibited dose-linear pharmacokinetic properties
between 0.3 and 30 mg/kg QW. Among the covariates
assessed, CrCL (calculated based on the Cockcroft-Gault
formula) had the most pronounced effect on CL. Across the
range of CrCL values collected in these 2 studies, the rela-
tionship between CL and CrCL was approximately linear
(R
2, 0.33; CL, 43 mL/h ? 0.356 9 CrCL) (Fig. 1). For Vc,
body weight and sex were signiﬁcant covariates (Supple-
mental Table 1). No signiﬁcant trends were seen when
laboratory values for albumin, alkaline phosphatase, total
bilirubin, S-aspartate aminotransferase, and S-alanine ami-
notransferase were plotted against the interindividual vari-
ability of CL or Vc from the base model. Mean AMG 386
CL based on the estimated individual CL was similar
across the phase 1 monotherapy study (0.075 ± 0.020 L/h)
and the phase 2 combination study (0.084 ± 0.026 L/h),
suggesting that concomitant administration of paclitaxel did
not affect the pharmacokinetics of AMG 386. The typical
CL(0.072L/h)forAMG386wasfasterthanformonoclonal
antibodies [25, 26].
Exposure–response analysis
Univariate analysis demonstrated an exposure–response
relationship between AUCss and PFS within each 1-unit
increment in predicted AUCss (e.g., AUCss of 9 vs.
8 mg h/mL) for all patients who received AMG 386 (HR,
0.97; P = 0.097). Similar relationships were seen in subset
analyses of the placebo and AMG 386 3 mg/kg arms
combined (HR, 0.90; P = 0.121) and the AMG 386 3 mg/kg
and 10 mg/kg arms combined (HR, 0.97; P = 0.23) as well
as the 10 mg/kg arm alone (HR, 0.89; P = 0.069). The
relationship between AUCss and PFS remained (adjusted
HR, 0.87, P = 0.045) in the 10 mg/kg arm after adjusting
for potential confounding factors (platinum sensitivity,
baseline CA-125, and progression on or within 6 months of
previous chemotherapy; Table 1), indicating that the trend
was likely due to a true exposure–response relationship
rather than a correlation between a potential confounder
and AUCss. These results also suggested that the maximum
effect on PFS was not achieved with a dose of 10 mg/kg
QW.
An AMG 386 AUCss of 9.6 mg h/mL (the 75th percen-
tile of median AUCss among patients administered
AMG 386) was selected as a cut point for further analysis.
Although the effect of higher AMG 386 AUCss on clinical
beneﬁt was also analyzed, 9.6 mg h/mL was selected to
ensure that a sufﬁcient number of patients were included in
safety and efﬁcacy evaluations. Figure 2 shows Kaplan–
Meier curves for estimated PFS when patients were grouped
CrCl
(mL/min)
(140–age) × actual body weight (kg)
72 × serum creatinine (mg/dL)
( × 0.85 for women) =
Observed CrCL, mL/min
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Fig. 1 Population pharmacokinetic analysis shows a linear correla-
tion between AMG 386 clearance (CL) and creatinine clearance
(CrCL)
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123by the dose of AMG 386 administered or by AUCss. Patients
with high exposure to AMG 386 (AUCss C 9.6 mg h/mL)
showed a more marked separation in PFS curves versus
placebo, compared with patients in the low-exposure group
(AUCss\9.6 mg h/mL). Median PFS was 4.6 months
(95% CI, 1.9–6.7) among placebo patients (n = 55),
8.1 months (95% CI, 6.4–10.8) among patients with
AUCss C 9.6 mg h/mL (n = 26; HR vs. placebo, 0.67
[95% CI, 0.40–1.14]), and 5.7 months (95% CI, 4.6–7.5)
among patients with AUCss\9.6 mg h/mL (n = 79; HR
vs. placebo, 0.81 [95% CI, 0.55–1.21]).
Exposure-safety analysis
A descriptive exposure-safety analysis did not reveal any
clinicallyrelevantdifferencesintheincidenceofAEsamong
patients with high (AUCss C 9.6 mg h/mL) and low
(AUCss\9.6 mg h/mL) AMG 386 exposure (Table 2).
No relationship between AUCss and grade C 3 adverse
events was observed. Differences were seen between some
AEs (e.g., peripheral neuropathy, arthralgia), but the study
was not powered to detect statistically signiﬁcant differ-
ences in the incidence of individual AEs. Additionally,
these toxicities are commonly associated with paclitaxel
administration and, therefore, may be attributed to longer
duration of chemotherapy administration in this patient
subset rather than to AMG 386 administration.
Simulation and dose assessment
Figure 3 shows the distributions of the predicted AUCss
with AMG 386 at a dose of 15 mg/kg QW and the actual
AUCss data that were seen with administration of 3 or
10 mg/kg QW (phase 2 combination study), or 30 mg/kg
Table 1 Multivariate model for PFS using a forward selection
algorithm
Factor AMG 386 10 mg/kg QW ?
Paclitaxel
Hazard ratio for PFS
a
(95% CI)
AUCss 0.869 (0.758–0.997)
P = 0.045
b
Baseline log (CA-125) 1.309 (1.076–1.593)
P = 0.007
b
Progressive disease within 6 months
of last chemotherapy
0.114 (0.013–0.961)
P = 0.046
b
Platinum sensitivity
PFI[12 months Reference
c
PFI 6–12 months 0.813 (0.304–2.176)
P = 0.680
b
Refractory to ﬁrst-line treatment 33.986 (2.892–399.450)
P = 0.005
b
Refractory to second-line or
subsequent treatment
7.119 (0.615–82.430)
P = 0.116
b
PFI\6 months 14.441 (1.393–149.741)
P = 0.025
b
Baseline log (CA-125), progressive disease within 6 months of last
chemotherapy, and platinum sensitivity were selected using forward
selection (up to a 3-factor model) modeling PFS in the placebo arm
AUCss, steady-state area under the concentration-versus-time curve;
PFI, platinum-free interval; PFS, progression-free survival; RECIST,
Response Evaluation Criteria in Solid Tumors; QW, once weekly
a PFS was a composite endpoint based on time from randomization to
progression per RECIST, clinical progression, CA-125 progression,
or death
b P values were determined using a Wald test in Cox regression
c Hazard ratios were calculated based on comparison with the
PFI[12-month group
AMG 386 AUCss
AMG 386 AUCss
Placebo 
100
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B
Fig. 2 Kaplan–Meier plots of progression-free survival (PFS; per
Response Evaluation Criteria in Solid Tumors, clinical progression or
CA-125 progression, or death) stratiﬁed by treatment arm (a)o r
exposure to C9.6 or \9.6 mg h/mL (b). AUCss, steady-state area
under the concentration-versus-time curve; QW, once weekly
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123QW (phase 1 monotherapy study). At a dose of 15 mg/kg
QW, [90% of patients were predicted to achieve
an AUCss C 9.6 mg h/mL, which is well below the
median AUCss (24.9 mg h/mL) reported for a dose of
30 mg/kg.
Among the various survival functions assessed, the Wei-
bulldistributionhadthelowestAkaikieInformationCriterion
and, therefore, was used to describe the PFS data. The para-
metric model with Weibull distribution was subsequently
used to characterize the simulated PFS data for AMG 386
Table 2 Exposure-safety analysis
Week 1 AUCss\9.6 mg h/mL
n = 79
Week 1 AUCss C 9.6 mg h/mL
n = 26
Placebo ? Paclitaxel
n = 55
All grades Grade C 3 All grades Grade C 3 Difference (95% CI)
a All grades Grade C 3
Adverse events occurring with a C14% difference in incidence in patients with AUCss C 9.6 mg h/mL versus those
with AUCss\9.6 mg h/mL, n (%)
Peripheral edema 44 (56) 5 (6) 20 (77) 0 (0) 21 (-2 to 39) 12 (22) 2 (4)
Diarrhea 27 (34) 2 (3) 14 (54) 1 (4) 20 (-4 to 41) 15 (27) 0 (0)
Peripheral neuropathy 22 (28) 4 (5) 12 (46) 2 (8) 18 (-4 to 40) 17 (31) 2 (4)
Neutropenia 17 (22) 9 (11) 1 (4) 0 (0) -18 (-29 to 2) 7 (13) 2 (4)
Arthralgia 12 (15) 0 (0) 9 (35) 0 (0) 20 (0 to 42) 8 (15) 0 (0)
Urinary tract infection 11 (14) 1 (1) 8 (31) 0 (0) 17 (-2 to 39) 7 (13) 0 (0)
Chest pain 4 (5) 0 (0) 6 (23) 0 (0) 18 (2 to 39) 4 (7) 0 (0)
Rhinorrhea 3 (4) 0 (0) 6 (23) 0 (0) 19 (4 to 40) 3 (5) 0 (0)
Chest discomfort 3 (4) 0 (0) 6 (23) 0 (0) 19 (4 to 40) 1 (2) 0 (0)
Mouth ulceration 4 (5) 0 (0) 5 (19) 0 (0) 14 (0 to 35) 3 (5) 0 (0)
Dry skin 1 (1) 0 (0) 5 (19) 0 (0) 18 (4 to 39) 3 (5) 0 (0)
Hyperhidrosis 1 (1) 0 (0) 4 (15) 0 (0) 14 (2 to 34) 1 (2) 0 (0)
AUCss, steady-state area under the concentration-versus-time curve
a Percentage difference (and 95% CI) between the AUCss C 9.6 mg h/mL group minus the AUCss\9.6 mg h/mL group for any grade adverse
event
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human study (c)
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123dosesof0(placebo),3,10,and15mg/kgincombinationwith
paclitaxel. The Kaplan–Meier PFS curves predicted by the
Weibull modelfor placebo and for 3 and 10 mg/kg QW were
consistent with the actual PFS curves for patients in the cor-
responding treatment arms, as were the HRs for comparison
with placebo (Fig. 4a–c). This ﬁnding conﬁrms the adequacy
ofthesimulateddataandﬁttedparametricsurvivalmodel,and
the consistency of the simulated data with outcomes among
patients with AUCss C 9.6 mg h/mL. Additionally, the pre-
dicted Kaplan–Meier PFS curve for an AMG 386 dose of
15 mg/kg QW was similar to the actual curve based on data
from patients in the AUCss C 9.6 mg h/mL group (Fig. 4d).
The predicted median PFS at an AMG 386 dose of 15 mg/kg
QW was 8.2 months (95% CI, 5.4–11.9 months; HR, 0.56
[95% CI, 0.31–1.07]).
Discussion
This study describes an important but infrequently used
application of population pharmacokinetic/pharmacody-
namic modeling to guide dose selection for phase 3 studies
of an antiangiogenic agent. Attrition rates for investiga-
tional cancer therapeutics are high [27]. Regulatory guid-
ance and the published literature suggest that the integration
of pharmacokinetic, pharmacodynamic, and clinical end-
point data may better inform future study design and help
maximize the risk–beneﬁt proﬁle for therapeutics [28–30].
In particular, exposure–response modeling may aid in the
rational selection of doses for further investigation [31, 32].
The failure of some cancer therapeutics in development
may be due to the conventional approach to dose selection,
which primarily focuses on the determination of the maxi-
mum tolerated dose [33], whereas identiﬁcation of an
‘‘optimal biologic dose’’ may be more appropriate for tar-
geted agents [34]. Consistent with this approach, a number
of recent phase 1 studies have used exposure–response
modeling to assess the relationship between exposure and a
marker of biologic activity to facilitate dose selection
[35–39]. However, because these markers have not been
clinically validated, the appropriateness of such analyses
for use in dose selection has been uncertain [40].
The present study was a prospectively planned phar-
macokinetic/pharmacodynamic analysis that assessed the
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Fig. 4 Predicted versus observed Kaplan–Meier estimates of pro-
gression-free survival (PFS). a Paclitaxel plus placebo; b AMG 386
3 mg/kg once weekly (QW); c AMG 386 10 mg/kg QW; d AMG 386
15 mg/kg QW (data source: AUCss C 9.6 mg h/mL; n = 26).
Graphs depict 1,000 replicates of 1,000 patients for each dose
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123relationship between exposure (AUCss) and a key clinical
outcome (PFS) to guide dose selection for phase 3 studies
of AMG 386 in recurrent ovarian cancer. The population
pharmacokinetic part of the analysis revealed that CrCL, a
measure of renal function, appears to be a signiﬁcant
covariate for AMG 386 CL. The relationship suggests that
renal disposition may play a role in the elimination of
AMG 386, which, at a size of approximately 65 kDa, is a
fairly large molecule. Renal clearance is uncommon for
biologic therapeutics, such as monoclonal antibodies, and,
to our knowledge, has not been described previously.
Estimated glomerular ﬁltration rate (calculated using the
Modiﬁcation of Diet in Renal Disease, MDRD, method),
which is another measure of renal function, also showed a
signiﬁcant effect on AMG 386 CL (data not shown). This
further supports our ﬁnding that the kidney may be
implicated in the elimination of AMG 386. However,
the exact mechanism of the effect of CrCL on the CL of
AMG 386 remains uncertain and warrants further
investigation.
Exposure–response analysis revealed a robust relation-
ship between AMG 386 exposure and PFS, suggesting that
maximum clinical beneﬁt was not reached at a dose of
10 mg/kg QW. The exposure-PFS relationship remained
after adjusting for potential confounding factors in the
multivariate analysis. However, given the relatively small
sample size of the phase 2 study, other unknown confound-
ing factors may have introduced an unidentiﬁed bias. Using
the results from the simulations based on the parametric
survival model, an AMG 386 dose of 15 mg/kg QW in
combination with cytotoxic chemotherapy has been pro-
posed for phase 3 studies in patients with recurrent ovarian
cancer (TRINOVA-1 [ClinicalTrials.gov, NCT01204749]
and TRINOVA-2 [ClinicalTrials.gov, NCT01281254]).
Although the toxicity of this dose when combined with
paclitaxel has not yet been directly tested, the exposure-
safety analysis presented here suggests that 15 mg/kg of
AMG 386 will have a similar safety proﬁle as the 10 mg/kg
dose. There were no marked differences in the incidence of
grade C 3 AEs between patients with high and low AMG
386 exposure, and the primary analysis did not show any
apparent dose-related trends in toxicity when comparing 3
and 10 mg/kg QW administered in combination with pac-
litaxel [17]. In the phase 1 study, 30 mg/kg QW (the maxi-
mum tested dose) was well tolerated as monotherapy [18].
Exposure–response relationships appear to be inﬂu-
enced by a number of factors, which can complicate
efforts to identify an optimal biological exposure
(OBE) and optimal biological dose (OBD) for a given
anticancer agent. OBDs and OBEs from monotherapy
dose-escalation studies in mixed solid tumors may not
translate into later-stage studies (monotherapy or com-
bination therapy) of single tumor types. For example, not
all clinical studies of the anti-VEGF-A antibody bev-
acizumab have shown a consistent dose–response rela-
tionship, suggesting that different optimum doses may be
needed for different tumor types or disease characteris-
tics [41]. Furthermore, an agent’s OBE may differ
between in vitro models and clinical studies. The AMG
386 OBE for antitumor efﬁcacy in xenograft models [16]
appeared to be lower than that identiﬁed in the phase 2
ovarian cancer study. This may reﬂect differences in
receptor occupancy across species, which has been
observed in other contexts [42].
Our study demonstrates the use of a novel model-based
approach to dose selection for a phase 3 study of an
investigational targeted therapy. Applying this technique to
the decision-making process in the development of anti-
cancer agents, for which dose-ranging studies are rarely
performed [8], provides important opportunities. Integrat-
ing results from preclinical pharmacokinetic, pharmaco-
logic, and toxicity studies into appropriate models can
guide the design of early clinical studies and inform the
interpretation of its results, thus supporting the fast tran-
sition of a promising molecule from discovery into the
clinic. Go/no-go decisions during continued clinical
development and dose selection for late-stage studies can
also be successfully supported by modeling applications.
Thus, quantitative (such as pharmacokinetic/pharmacody-
namic and/or exposure–response) modeling and simula-
tions can guide each step of a clinical development plan
from early discovery through pivotal phase 3 studies [1].
However, this approach is often limited because it requires
early integration of pharmacometric scientists in the clin-
ical decision-making process as well as the timely devel-
opment of relevant models.
In summary, our study demonstrates how exposure–
response analyses of phase 2 study data and the application
of pharmacokinetic/pharmacodynamic models can assist in
the selection of doses for subsequent phase 3 studies of an
antiangiogenic therapeutic.
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